Clinical Trial

Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial

Study acronym: CAN-CHA
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Chronic headaches are a major cause of disability among adolescents. Cannabis products have supported the management of headaches in adults and may play a role in pediatric chronic pain. We propose a multisite, open-label, tolerability study conducted across three centers in Canada of Cannabidiol-enriched Cannabis Herbal Extract in adolescents (ages 14 to 17 years old) with chronic headaches. The study includes a one month baseline assessment, four months of escalating treatment doses and a weaning period. Our primary outcome is tolerability defined as the number and severity of reported adverse events.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-04-14; most recent amendment 2025-05-22.
Status change: Not Yet Recruiting → Recruiting 2023-11-27
Trial Details
NCT Number NCT05337033
Lead Sponsor University of Manitoba
Collaborators: SickKids Foundation
Conditions Chronic Migraine
Enrollment 20 participants
Start Date 2024-10-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-29